

**PR.21: A RANDOMIZED PHASE II STUDY OF 177LU-PSMA-617 Vs. DOCETAXEL IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND PSMA-POSITIVE DISEASE WORKSHOP**

CHELSEA HOTEL, TORONTO, ON

ROOM: CHURCHILL BALLROOM B

SATURDAY MAY 4<sup>TH</sup>, 2024, 8:00 AM – 10:00 AM

STUDY CHAIRS: KIM CHI, FRANÇOIS BERNARD, AND FRED SAAD  
SENIOR INVESTIGATOR: WENDY PARULEKAR

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

- To provide an overview of the clinical applications of PSMA radioligand therapy in clinical practice
- To review and discuss the clinical and research objectives of the CCTG PR.21 trial
- To develop analysis priorities and associated timelines for the CCTG PR.21 trial

---

<b>08:00 am</b>	Welcome and Introductions	<b>Wendy Parulekar</b>
<b>08:05 am</b>	Overview of CCTG PR.21; Trial objectives, design and current status	<b>Kim Chi</b>
<b>08:20 am</b>	Biological Correlative Analyses: Biobank status, planned correlative assays, timelines	<b>Alex Wyatt</b>
<b>09:00 am</b>	Lu PSMA Dosimetry Correlative Analyses: Update on research to date, planned correlative assays, timelines	<b>Francois Benard Carlos Uribe</b>
<b>09:40 am</b>	Next steps – Potential Additional Analyses	<b>All</b>

